113. Muscular dystrophy
567 clinical trials,   442 drugs   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02525302
(ClinicalTrials.gov)
May 201518/7/2015HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02HT-100 Long-term Safety and Pharmacodynamics in Patients With DMD Who Have Completed Protocols HALO-DMD-01 and HALO-DMD-02Duchenne Muscular DystrophyDrug: HT-100Akashi TherapeuticsNULLTerminated6 Years20 YearsMale10Phase 2United States
2NCT01978366
(ClinicalTrials.gov)
October 201331/10/2013Open Label Extension Study of HT-100 in Patients With DMDAn Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01Duchenne Muscular DystrophyDrug: HT-100Processa PharmaceuticalsNULLTerminated6 Years20 YearsMale17Phase 2United States
3NCT01847573
(ClinicalTrials.gov)
May 20132/5/2013Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular DystrophyA Phase 1b Open Label, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT-100 in Patients With Duchenne Muscular DystrophyDuchenne Muscular DystrophyDrug: HT-100Processa PharmaceuticalsNULLTerminated6 Years20 YearsMale17Phase 1;Phase 2United States